ALERTS & COVID-19 UPDATES Learn more: COVID-19 Resources; COVID-19 Testing; Vaccine Info; Visitor Policy; Support Us

[LCID Study Number: 2018-024]

A phase II, multicenter, open-label, randomized two-year study to evaluate the efficacy and safety of deferasirox film-coated tablet versus phlebotomy in patients with Hereditary Hemochromatosis

The main objective is to eliminate the need for repeated needle sticks required for phlebotomy which is more beneficial for the patient. The study drug deferasirox is a high affinity oral iron chelator that binds iron and facilitates fecal excretion of the chelator-iron complex. The Standard of care treatment for patients with symptomatic HH is initial frequent therapeutic phlebotomy until acceptable iron studies are achieved followed by intermitted life-long phlebotomy guided by serum iron levels. Oral iron chelating agents are also employed in some patients.

Primary Contact Email: [email protected]

Primary Contact Phone: 781-744-3025